October 2025 Med Tech-related health technology assessments from the NIHR in England

The National Institute for Health and Care Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform the National Institute for Health and Care Excellence (NICE) guidance. 

In October 2025, four Med Tech-related assessments were published in the NIHR HTA Journal. Examples of evaluations are provided below:

• Tumor profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation based on a systematic review and economic evaluation.  The study aimed to evaluate the effectiveness and cost-effectiveness of four tumor profiling tests (Oncotype DX, Prosigna, EPclin, and MammaPrint), compared with current decision-making (no testing), to guide the use of adjuvant chemotherapy in people with hormone-receptor-positive, human epidermal growth factor receptor two-negative, early-stage breast cancer with one to three positive lymph nodes. It was concluded that all four tests provide prognostic information on the risk of relapse. The evidence predicting relative chemotherapy benefit is weaker and mostly limited to Oncotype DX. The economic analyses suggest that Oncotype DX and EPclin may have favorable cost-effectiveness profiles in postmenopausal lymph node-positive subgroups, although this remains uncertain.
• Algorithm-based remote monitoring of heart failure risk data in people with cardiac implantable electronic devices based on a systematic review and cost-effectiveness analysis. The study aimed to determine the clinical and cost-effectiveness of the four remote monitoring algorithms (CorVue, HeartInsight, HeartLogic, and TriageHF) for detecting heart failure in people with cardiac implantable electronic devices. It was concluded that there was a lack of comparative evidence across all technologies included in the scope. Evidence for HeartLogic and TriageHF suggests that they may have acceptable prognostic accuracy for predicting heart failure events. However, further evidence is required to confirm these results. It is likely that remote monitoring systems for CorVue, HeartInsight, HeartLogic, and TriageHF would be cost-effective if they were to result in fewer hospitalizations in heart failure patients.

Other assessments published in October 2025 focused on the clinical and cost-effectiveness of microstructural scaffolds in patients undergoing microfracture for symptomatic chondral or osteochondral defects of the knee, as well as rapid diagnostic tests to inform clinical decision-making for antifungal stewardship in the Intensive Care Unit (ICU).

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.